USD10
INBX Shares
About Inhibrx BiosciencesInhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
USD10
INBX Shares
About Inhibrx BiosciencesInhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.32B
OPEN PRICE
$89.83
LOW (1Y)
$28.16
HIGH (1Y)
$155.29
LOW (24H)
$87.73
HIGH (24H)
$90.72
VOLUME (24H)
$146.45K
35.33%
Price history
Time | Price | Change |
|---|---|---|
Today | $89.83 | 0.00% |
1 Day | $89.10 | |
1 Week | $99.21 | |
1 Month | $105.43 | |
1 Year | $38.22 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Learn how to buy popular cryptocurrencies
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.